Chugai Pharmaceutical Co., Ltd.
4519
株式のランク
#356
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
株価
$41.71
最終同期: 2026-10-16
時価総額
$68.64B
変化（1日）
2.01%
変化（1年）
-14.16%
国
JP
取引 Chugai Pharmaceutical Co., Ltd. (4519)
カテゴリー
Healthcare
の時価総額 Chugai Pharmaceutical Co., Ltd.(4519)
時価総額: $68.64B
October 2026時点で、Chugai Pharmaceutical Co., Ltd. の時価総額は $68.64B です。これは、当社のデータによると、Chugai Pharmaceutical Co., Ltd. が世界で356th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Chugai Pharmaceutical Co., Ltd. の時価総額の履歴（2000 から 2026 まで）
